Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

clear all | select all

Conference Years:

clear all | select all

Days Within Meeting:

clear all | select all

Conferences:

Availability:

clear all | select all

Participation Type:

clear all | select all

Topic Tracks*:

clear all | select all

Organ Site Tracks*:

Showing session: reset

Concurrent Session 3: What Is the Current Role and Impact of CRISPR Screening to Define Therapeutic Targets in Lymphoma?

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 3 of 3
Concurrent Session 3: What Is the Current Role and Impact of CRISPR Screening to Define Therapeutic Targets in Lymphoma?
Using in vivo CRISPR-based screening to identify lymphoma drug targets
Michael T Hemann
David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, United States
from 2018 Advances in Malignant Lymphoma conference on June 24, 2018 7:15 AM-8:00 AM
Concurrent Session 3: What Is the Current Role and Impact of CRISPR Screening to Define Therapeutic Targets in Lymphoma?
  •  
  • Permission not
    granted for presentation
  •  
  •  
What is the current role and impact of CRISPR screening to define therapeutic targets in lymphoma?
Sandeep S Dave
Duke Univ., Chapel Hill, NC, United States
from 2018 Advances in Malignant Lymphoma conference on June 24, 2018 7:15 AM-8:00 AM
Concurrent Session 3: What Is the Current Role and Impact of CRISPR Screening to Define Therapeutic Targets in Lymphoma?
  •  
  • Permission not
    granted for presentation
  •  
  •  
Crispr-Cas9 screens interrogate lymphoma biology and lead to therapies
Hans-Guido Wendel
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
from 2018 Advances in Malignant Lymphoma conference on June 24, 2018 7:15 AM-8:00 AM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 3 of 3